Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats
John W. Ward, Alan R. Hinman
Gastroenterology (2018) Vol. 156, Iss. 2, pp. 297-310
Closed Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

Global Elimination of Chronic Hepatitis
David L. Thomas
New England Journal of Medicine (2019) Vol. 380, Iss. 21, pp. 2041-2050
Closed Access | Times Cited: 282
Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people
Zhenqiu Liu, Chunqing Lin, Xianhua Mao, et al.
Gut (2023) Vol. 72, Iss. 12, pp. 2354-2363
Open Access | Times Cited: 52
Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches
Paola Fisicaro, Valeria Barili, Marzia Rossi, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 110
Transition in the etiology of liver cirrhosis in Japan: a nationwide survey
Hirayuki Enomoto, Yoshiyuki Ueno, Yoichi Hiasa, et al.
Journal of Gastroenterology (2019) Vol. 55, Iss. 3, pp. 353-362
Open Access | Times Cited: 88
The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019
Jia Yang, Jinlei Qi, Xiaoxiao Wang, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 35
The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals
Stephanie Popping, Debora Bade, Charles A. Boucher, et al.
Journal of Virus Eradication (2019) Vol. 5, Iss. 1, pp. 60-66
Open Access | Times Cited: 68
The cGAS-STING Pathway: Novel Perspectives in Liver Diseases
Dongwei Xu, Yizhu Tian, Qiang Xia, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 51
HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications
Carolina Boni, Valeria Barili, Greta Acerbi, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 11, pp. 2754-2754
Open Access | Times Cited: 49
E3 ubiquitin ligase TRIM21 restricts hepatitis B virus replication by targeting HBx for proteasomal degradation
Yahui Song, Min Li, Yanqi Wang, et al.
Antiviral Research (2021) Vol. 192, pp. 105107-105107
Closed Access | Times Cited: 36
Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination
Nathalie Brunner, Philip Bruggmann
Journal of Preventive Medicine and Public Health (2021) Vol. 54, Iss. 4, pp. 251-258
Open Access | Times Cited: 36
Hybrid-Capture Target Enrichment in Human Pathogens: Identification, Evolution, Biosurveillance, and Genomic Epidemiology
Zheng Bin Randolph Quek, Sock Hoon Ng
Pathogens (2024) Vol. 13, Iss. 4, pp. 275-275
Open Access | Times Cited: 5
Prospects for Controlling Hepatitis B Globally
Vincent Soriano, Víctor Moreno‐Torres, Ana Treviño, et al.
Pathogens (2024) Vol. 13, Iss. 4, pp. 291-291
Open Access | Times Cited: 5
Acute hepatitis B notification rates in Flanders, Belgium, 2009 to 2017
Özgür M. Koc, Pierre Van Damme, Dana Busschots, et al.
Eurosurveillance (2019) Vol. 24, Iss. 30
Open Access | Times Cited: 39
Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Hadar Meringer, Oren Shibolet, Liat Deutsch
World Journal of Gastroenterology (2019) Vol. 25, Iss. 29, pp. 3929-3940
Open Access | Times Cited: 36
Targeting hepatitis B virus cccDNA levels: Recent progress in seeking small molecule drug candidates
Yu Jin, Shuo Wang, Shujing Xu, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 7, pp. 103617-103617
Open Access | Times Cited: 11
Design and biochemical evaluation of 2-cyclopropyl-thioureidobenzamide (CP-TBA) derivatives as potent HBV capsid assembly modulators targeting a novel binding site
Mei Wang, Yutong Dou, Aixin Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117441-117441
Closed Access
Disease burden of viral hepatitis A, B, C and E: A systematic analysis
Zhenqiu Liu, Oumin Shi, Tiejun Zhang, et al.
Journal of Viral Hepatitis (2020) Vol. 27, Iss. 12, pp. 1284-1296
Closed Access | Times Cited: 31
Spatiotemporal heterogeneity and impact factors of hepatitis B and C in China from 2010 to 2018: Bayesian space–time hierarchy model
Jiaojiao Qian, Ming Yue, Peng Huang, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 9
Chaperone-Mediated Autophagy in the Liver: Good or Bad?
Srikanta Dash, Yücel Aydın, Krzysztof Moroz
Cells (2019) Vol. 8, Iss. 11, pp. 1308-1308
Open Access | Times Cited: 27
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine
Malvika Verma, Jacqueline N. Chu, John A. F. Salama, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 22, pp. 11987-11994
Open Access | Times Cited: 24
Hepatitis C virus micro-elimination: Where do we stand?
Alessandra Mangia, Rosa Cotugno, Giovanna Cocomazzi, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 16, pp. 1728-1737
Open Access | Times Cited: 22
<p>Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy</p>
Thomas G. Cotter, Donald M. Jensen
Drug Design Development and Therapy (2019) Vol. Volume 13, pp. 2565-2577
Open Access | Times Cited: 25
Viral hepatitis as a risk factor for the development of hepatocellular carcinoma
Saleh A. Alqahtani, Massimo Colombo
Hepatoma Research (2020) Vol. 2020
Open Access | Times Cited: 22
Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study
Qing‐Lei Zeng, Hongxu Zhang, Jiyuan Zhang, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 12, pp. 2826-2837.e9
Closed Access | Times Cited: 19
Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma
Saleh A. Alqahtani, Massimo Colombo
Cells (2021) Vol. 10, Iss. 11, pp. 3091-3091
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top